Bicocca Open Archive

Logo unimib boa
COLOMBO, NICOLETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.363
EU - Europa 7.754
AS - Asia 4.494
SA - Sud America 66
AF - Africa 28
Continente sconosciuto - Info sul continente non disponibili 27
OC - Oceania 26
Totale 34.758
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.982
CN - Cina 1.464
SG - Singapore 1.392
IE - Irlanda 1.377
IT - Italia 1.370
RU - Federazione Russa 1.256
UA - Ucraina 990
SE - Svezia 955
HK - Hong Kong 847
DE - Germania 478
GB - Regno Unito 443
CA - Canada 367
FI - Finlandia 286
ID - Indonesia 242
VN - Vietnam 177
AT - Austria 149
FR - Francia 146
IN - India 100
NL - Olanda 99
TR - Turchia 83
JP - Giappone 81
DK - Danimarca 57
BR - Brasile 40
ES - Italia 29
BE - Belgio 25
AU - Australia 22
KR - Corea 22
EU - Europa 20
TW - Taiwan 19
IR - Iran 16
RO - Romania 16
CL - Cile 13
MX - Messico 13
ZA - Sudafrica 11
PL - Polonia 9
BG - Bulgaria 8
GR - Grecia 8
A2 - ???statistics.table.value.countryCode.A2??? 7
CH - Svizzera 7
CZ - Repubblica Ceca 7
NO - Norvegia 7
PH - Filippine 7
PK - Pakistan 6
MA - Marocco 5
MD - Moldavia 5
MK - Macedonia 5
PT - Portogallo 5
CO - Colombia 4
EG - Egitto 4
MY - Malesia 4
RS - Serbia 4
AE - Emirati Arabi Uniti 3
AR - Argentina 3
IL - Israele 3
KZ - Kazakistan 3
LB - Libano 3
MU - Mauritius 3
NZ - Nuova Zelanda 3
QA - Qatar 3
TH - Thailandia 3
UZ - Uzbekistan 3
AL - Albania 2
BD - Bangladesh 2
HR - Croazia 2
HU - Ungheria 2
LK - Sri Lanka 2
LT - Lituania 2
MO - Macao, regione amministrativa speciale della Cina 2
PE - Perù 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
FK - Isole Falkland (Malvinas) 1
GH - Ghana 1
GI - Gibilterra 1
IQ - Iraq 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
LU - Lussemburgo 1
MN - Mongolia 1
MT - Malta 1
NG - Nigeria 1
NP - Nepal 1
PF - Polinesia Francese 1
SA - Arabia Saudita 1
SC - Seychelles 1
UG - Uganda 1
Totale 34.758
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.337
Woodbridge 2.684
Fairfield 2.357
Houston 1.888
Dublin 1.296
Jacksonville 1.191
Singapore 1.174
Ashburn 1.036
Wilmington 1.007
Seattle 874
Hong Kong 827
Cambridge 787
Dearborn 736
Chandler 695
Princeton 639
New York 594
Santa Clara 429
Milan 358
Lawrence 315
Altamura 290
Nanjing 279
Frankfurt am Main 268
Jakarta 236
Lachine 202
Beijing 195
Vienna 146
San Diego 143
Andover 125
Shanghai 110
Boardman 103
Guangzhou 101
Dong Ket 96
Toronto 90
London 86
Nanchang 85
Shenyang 70
Falls Church 69
Rome 69
Helsinki 62
Hebei 60
Tianjin 57
Ottawa 54
Norwalk 51
Mountain View 49
Changsha 48
Hamburg 47
Chicago 45
Jiaxing 42
Redmond 41
Hangzhou 39
Huizen 38
Los Angeles 37
Jinan 29
Kunming 28
Zhengzhou 26
Fremont 25
Tokyo 25
University Park 25
Pune 22
Brussels 19
Lappeenranta 19
Ningbo 18
Gaithersburg 17
Hanoi 16
Hyderabad 16
Detroit 15
San Mateo 15
Turin 15
Hefei 14
São Paulo 14
Lissone 13
Taipei 13
Chengdu 12
Dallas 12
Washington 12
Amsterdam 11
Hounslow 11
Kilburn 11
Moscow 11
Naples 11
Florence 10
Groningen 10
Melbourne 10
Nuremberg 10
Phoenix 10
Arezzo 9
Bologna 9
Madrid 9
Sacramento 9
Auburn Hills 8
Desio 8
Edmonton 8
Johannesburg 8
Palermo 8
Panvel 8
San Jose 8
Taizhou 8
Carate Brianza 7
Genova 7
Kiev 7
Totale 26.303
Salva come PNG Salva come JPEG
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 486
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer 253
Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220) 229
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 210
Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study 205
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 204
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer 201
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 199
CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells 191
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study 185
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 185
FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer 180
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12 172
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 171
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 169
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series 166
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial 166
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation 162
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial 159
Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum 158
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 157
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer 157
Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells 153
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial 151
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 150
Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy 149
Reply to M.L. Friedlander et al 149
The disposition of carboplatin in ovarian cancer patients 148
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 147
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer 146
Low-dose oral etoposide in epithelial cancer of the ovary 146
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 146
A reassessment of the role of second-look laparotomy in advanced ovarian cancer 145
Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients 145
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin 145
Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB 145
Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients 145
DR antigen expression on ovarian carcinoma cells does not correlate with their capacity to elicit an autologous proliferative response 144
Neoadjuvant chemotherapy in cervical cancer: An update 144
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge 144
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 144
Chemo-conization in early cervical cancer 143
Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: A single institution prospective series 143
The role of surgery in gestational trophoblastic disease 142
Trabectedin as single agent in relapsed advanced ovarian cancer: Results from a retrospective pooled analysis of three phase II trials 141
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study 141
Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors 141
Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis 141
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial 141
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer intergroup 140
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 140
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups 140
Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells 139
Tumor-derived chemotactic factor(s) from human ovarian carcinoma: evidence for a role in the regulation of macrophage content of neoplastic tissues 139
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study 139
Treatment of advanced ovarian cancer (OC): A randomized trial comparing different platinum (P) combinations 138
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 138
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 136
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion 136
Antibody-dependent and -independent cytotoxicity of human mononuclear phagocytes: defective stimulation of tumoricidal activity in milk macrophages 136
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 135
Methotrexate with citrovorum factor in low-risk gestational trophoblastic tumor 135
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens 134
Aggressive angiomyxoma of the vulva 133
Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary 133
Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience 133
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial 133
Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer 132
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer 132
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status 132
Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case series 132
Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients 131
Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives 131
Robotic Surgery: Changing the Surgical Approach for Endometrial Cancer in a Referral Cancer Center 130
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 130
Early oral versus "traditional" postoperative feeding in gynecologic oncology patients undergoing intestinal resection: A randomized controlled trial 129
Fertility-sparing surgery in epithelial ovarian cancer: A systematic review of oncological issues 129
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer 129
Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients 128
Optimal treatment of early-stage ovarian cancer 128
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 128
Optimizing treatment of the partially platinum-sensitive ovarian cancer patient 127
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 126
Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: Results of a multicenter retrospective Italian study 126
Adult granulosa cell tumours of the ovary 126
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study 126
Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer 126
Defective natural killer activity within human ovarian tumors: Low numbers of morphologically defined effectors present in situ 125
Overexpression of p185 is not related to erbB2 amplification in ovarian cancer 125
Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities 125
Fertility-Sparing Options in Young Women with Cervical Cancer 125
Are monoclonal antibodies a safe treatment for cancer during pregnancy? 125
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors 124
Robotic Versus Open Radical Hysterectomy in Women With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: A Single-institution Experience of Surgical and Oncologic Outcomes 124
Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis 124
Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit 124
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 124
Management of ovarian stromal cell tumors 122
Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships 122
A phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14) 122
Totale 14.930
Salva come PNG Salva come JPEG
Categoria #
all - tutte 146.109
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 146.109
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.649 0 0 0 0 0 812 879 501 655 260 422 120
2020/20214.780 335 227 446 451 535 396 481 511 396 478 199 325
2021/20223.002 181 245 348 237 184 196 168 209 186 250 231 567
2022/20234.033 665 1.028 274 226 247 729 59 327 243 66 95 74
2023/20244.164 98 105 176 111 637 1.033 755 107 525 117 68 432
2024/20254.985 713 1.688 492 616 1.039 437 0 0 0 0 0 0
Totale 36.015